There were 1,149 press releases posted in the last 24 hours and 358,474 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image